Unique ID issued by UMIN | UMIN000002016 |
---|---|
Receipt number | R000002458 |
Scientific Title | Multi-Center Phase II Study on Efficacy of High-Slip Skin Care Pad for Hand-Foot Skin Reaction Caused by Sorafenib in Patients with Renal Cell Carcinoma |
Date of disclosure of the study information | 2009/05/29 |
Last modified on | 2014/04/08 01:23:18 |
Multi-Center Phase II Study on Efficacy of High-Slip Skin Care Pad for Hand-Foot Skin Reaction Caused by Sorafenib in Patients with Renal Cell Carcinoma
Study on Efficacy of High-Slip Skin Care Pad for HFSR by Sorafenib in Patients with Renal Cell Carcinoma
Multi-Center Phase II Study on Efficacy of High-Slip Skin Care Pad for Hand-Foot Skin Reaction Caused by Sorafenib in Patients with Renal Cell Carcinoma
Study on Efficacy of High-Slip Skin Care Pad for HFSR by Sorafenib in Patients with Renal Cell Carcinoma
Japan |
Renal cell carcinoma
Urology |
Malignancy
NO
To investigate the usefulness of a high-slip skin care pad (Remois® Pad) for Hand-Foot Skin Reaction (HFSR) on the soles of the feet when HFSR occurs with sorafenib treatment
Efficacy
Exploratory
Pragmatic
Phase II
Incidence of Grade 2 or 3 HFSR
Sorafenib treatment compliance (dose reduction/discontinuation), Pain assessment (VAS), Safety
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
YES
YES
Institution is not considered as adjustment factor.
NO
Central registration
2
Treatment
Maneuver |
High-slip skin care pad (Remois® Pad)
Change pads every 2-3 days. Maximum 4 weeks.
10% Urea cream
Apply and rub in well after clean affected site,2-3 times a day. Maximum 4 weeks.
20 | years-old | <= |
Not applicable |
Male and Female
1) Age: At least 20 years of age
2) Patients with confirmed unresectable or metastatic renal cell carcinoma
3)Patients within 8 weeks since the start of treatment with sorafenib
4) Patients with Grade 1HFSR
5) ECOG PS of 0 or 1
6) Patients who are expected to survive at least 12 weeks
7) Patients who give written informed consent prior to the study
1) Patients undergoing combination therapy with cytokine therapy, chemotherapy, or molecularly targeted therapy
2) Patients who have used other molecularly targeted drug therapy
3) Patients in whom the underlying disease is a generalized dermatological disease
4) Patients with Grade 2 or higher HFSR on the hands
5) Patients with Grade 3 or higher adverse events other than HFSR
6) Patients with previously confirmed sorafenib-induced HFSR
7) Patients determined to be unsuitable by investigators
8) Patients who may otherwise compromise patient safety in the conduct of the trial or who may compromise protocol compliance
100
1st name | |
Middle name | |
Last name | Nobuo Shinohara |
Hokkaido University Graduate School of Medicine
Department of Renal and Genitourinary Surgery
North-15,West-7,Kitaku Sapporo, Japan,060-3638
011-706-5966
1st name | |
Middle name | |
Last name | Nobuo Shinohara |
Hokkaido University Graduate School of Medicine
Department of Renal and Genitourinary Surgery
North-15,West-7,Kitaku Sapporo, Japan,060-3638
011-706-5966
Japanese Society of Renal Cancer (JSRC)
CReS Kyushu
Non profit foundation
NO
2009 | Year | 05 | Month | 29 | Day |
Published
Main results already published
2009 | Year | 05 | Month | 12 | Day |
2009 | Year | 05 | Month | 01 | Day |
2012 | Year | 04 | Month | 30 | Day |
2012 | Year | 05 | Month | 31 | Day |
2012 | Year | 05 | Month | 31 | Day |
2012 | Year | 08 | Month | 31 | Day |
2009 | Year | 05 | Month | 29 | Day |
2014 | Year | 04 | Month | 08 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002458